Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice.

Cortellini A, Cannita K, Parisi A, Lanfiuti Baldi P, Venditti O, D'Orazio C, Dal Mas A, Calvisi G, Giordano AV, Vicentini V, Vicentini R, Felicioni L, Marchetti A, Buttitta F, Russo A, Ficorella C.

Onco Targets Ther. 2019 Mar 25;12:2159-2170. doi: 10.2147/OTT.S194745. eCollection 2019.

2.

Looking for A Place for Dose-Dense TMZ Regimens in GBM Patients: An Experience with MGMT Exploratory Evaluation.

Napoleoni L, Cortellini A, Cannita K, Parisi A, Dal Mas A, Calvisi G, Venditti O, Baldi PL, Cocciolone V, Ricci A, Ficorella C.

Bioengineering (Basel). 2019 Jan 22;6(1). pii: E11. doi: 10.3390/bioengineering6010011.

3.

Where are we with treatment options after first line in small cell lung cancer?-report of two opposite cases treated with CAPTEM regimen and possible perspectives.

Cortellini A, Dal Mas A, Cannita K, Collina G, Parisi A, Pavese F, Porzio G, Verna L, Ficorella C.

J Thorac Dis. 2018 Jul;10(7):E520-E525. doi: 10.21037/jtd.2018.06.44. No abstract available.

4.

Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations.

Cocciolone V, Cannita K, Tessitore A, Mastroiaco V, Rinaldi L, Paradisi S, Irelli A, Baldi PL, Sidoni T, Ricevuto E, Dal Mas A, Calvisi G, Coletti G, Ciccozzi A, Pizzorno L, Resta V, Bafile A, Alesse E, Ficorella C.

Oncotarget. 2018 Jun 8;9(44):27380-27396. doi: 10.18632/oncotarget.25270. eCollection 2018 Jun 8.

5.

KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy.

Bruera G, Pepe F, Malapelle U, Pisapia P, Mas AD, Di Giacomo D, Calvisi G, Troncone G, Ricevuto E.

Oncotarget. 2018 May 29;9(41):26279-26290. doi: 10.18632/oncotarget.25180. eCollection 2018 May 29.

6.

Dose-finding study of intensive weekly alternating schedule of docetaxel, 5-fluorouracil, and oxaliplatin, FD/FOx regimen, in metastatic gastric cancer.

Bruera G, Massacese S, Galvano A, Mas AD, Guadagni S, Calvisi G, Ciacco E, Russo A, Ricevuto E; Oncology Network ASL1 Abruzzo, Italy.

Oncotarget. 2018 Apr 17;9(29):20339-20350. doi: 10.18632/oncotarget.24861. eCollection 2018 Apr 17.

7.

KRAS and 2 rare PI3KCA mutations coexisting in a metastatic colorectal cancer patient with aggressive and resistant disease.

Tessitore A, Bruera G, Mastroiaco V, Cannita K, Cortellini A, Cocciolone V, Dal Mas A, Calvisi G, Zazzeroni F, Ficorella C, Ricevuto E, Alesse E.

Hum Pathol. 2018 Apr;74:178-182. doi: 10.1016/j.humpath.2018.01.021. Epub 2018 Jan 31.

PMID:
29409955
8.

Platelet concentration in platelet-rich plasma affects tenocyte behavior in vitro.

Giusti I, D'Ascenzo S, Mancò A, Di Stefano G, Di Francesco M, Rughetti A, Dal Mas A, Properzi G, Calvisi V, Dolo V.

Biomed Res Int. 2014;2014:630870. doi: 10.1155/2014/630870. Epub 2014 Jul 23.

9.

External Quality Assessment (EQA) program for the preanalytical and analytical immunohistochemical determination of HER2 in breast cancer: an experience on a regional scale.

Terrenato I, Arena V, Pizzamiglio S, Pennacchia I, Perracchio L, Buglioni S, Ercolani C, Sperati F, Costarelli L, Bonanno E, Baldini D, Candia S, Crescenzi A, Dal Mas A, Di Cristofano C, Gomes V, Grillo LR, Pasquini P, Pericoli MN, Ramieri MT, Di Stefano D, Ruco L, Scarpino S, Vitolo D, d'Amati G, Paradiso A, Verderio P, Mottolese M.

J Exp Clin Cancer Res. 2013 Aug 21;32:58. doi: 10.1186/1756-9966-32-58.

10.

Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease.

Bruera G, Cannita K, Di Giacomo D, Lamy A, Troncone G, Dal Mas A, Coletti G, Frébourg T, Sabourin JC, Tosi M, Ficorella C, Ricevuto E.

BMC Med. 2012 Nov 8;10:135. doi: 10.1186/1741-7015-10-135.

Supplemental Content

Loading ...
Support Center